Thiosemicarbazones from the old to new: Iron chelators that are more than just ribonucleotide reductase inhibitors

Journal of Medicinal Chemistry

Volumn 52, Issue 17, 2009, Pages 5271-5294

  Yu, Yu ^a   Kalinowski, Danuta S ^a   Kovacevic, Zaklina ^a   Siafakas, Aritee R ^a   Jansson, Patric J ^a   Stefani, Christian ^a   Lovejoy, David B ^a   Sharpe, Philip C ^b   Bernhardt, Paul V ^b   Richardson, Des R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXY 1 NAPHTHYLALDEHYDE 2 THIOPHENECARBOXYL HYDRAZONE; 2 HYDROXY 1 NAPHTHYLALDEHYDE 3 CHLOROBENZOYL HYDRAZONE; 2 HYDROXY 1 NAPHTHYLALDEHYDE 3 FLUOROBENZOYL HYDRAZONE; ANTINEOPLASTIC AGENT; AROYLHYDRAZONE DERIVATIVE; CD71 ANTIGEN; CP 502; CYCLINE; DEFERIPRONE; DEFERIPRONE CONJUGATE; DEFERIPRONE DERIVATIVE; DEFERIPRONE SPERMINE CONJUGATE; DEFEROXAMINE; FERROUS ION; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRON; IRON CHELATING AGENT; POLYAMINE; PROTEIN; PROTEIN BNIP3; PROTEIN NDRG1; PROTEIN P53; PYRIDOXAL 3 FLUOROBENZOYL HYDRAZONE; PYRIDOXAL 4 TERT BUTYLBENZOYL HYDRAZONE; PYRIDOXAL ISONICOTINOYL HYDRAZONE; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE INHIBITOR; SPERMINE; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; CELL CYCLE; CELL METABOLISM; CELL PROLIFERATION; CYTOTOXICITY; DNA SYNTHESIS; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; GADD GENE; GENE; GROWTH INHIBITION; HUMAN; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRON CHELATION; IRON OVERLOAD; LIPOPHILICITY; MEMBRANE PERMEABILITY; METAL BINDING; NDRG1 GENE; NEUROBLASTOMA; NONHUMAN; OXIDATION REDUCTION REACTION; PH; PROTEIN EXPRESSION; REVIEW; STRUCTURE ACTIVITY RELATION; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; IRON; IRON CHELATING AGENTS; RIBONUCLEOTIDE REDUCTASES; THIOSEMICARBAZONES;

EID: 69949108747     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900552r     Document Type: Review

References (186)

1. Beraldo, H.; Gambino, D. The wide pharmacological versatility of semicarbazones, thiosemicarbazones and their metal complexes. Mini-Rev. Med. Chem. 2004, 4, 31-39.
2. Pedrido, R.; Gonzalez-Noya, A. M.; Romero, M. J.; Martinez-Calvo, M.; Vazquez Lopez, M.; Gomez-Forneas, E.; Zaragoza, G.; Bermejo, M. R. Pentadentate thiosemicarbazones as versatile chelating systems. A comparative structural study of their metallic complexes. Dalton Trans. 2008, 6776-6787.
3. Brockman, R. W.; Thomson, J. R.; Bell, M. J.; Skipper, H. E. Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone. Cancer Res. 1956, 16, 167-170.
4. Sartorelli, A. C.; Booth, B. A. Inhibition of the growth of sarcoma 180 ascites cells by combinations of inhibitors of nucleic acid biosynthesis and the cupric chelate of kethoxal bis-(thiosemicarbazone). Cancer Res. 1967, 27, 1614-1619.
5. Sartorelli, A. C.; Agrawal, K. C.; Moore, E. C. Mechanism of inhibition of ribonucleoside diphosphate reductase by a-(N)-heterocyclic aldehyde thiosemicarbazones. Biochem. Pharmacol. 1971, 20, 3119-3123.
6. Thelander, L.; Reichard, P. Reduction of ribonucleotides. Annu. Rev. Biochem. 1979, 48, 133-158.
7. Pandeya, S. N.; Sriram, D.; Nath, G.; DeClercq, E. Synthesis, antibacterial, antifungal and anti-HIV activities of Schiff and Mannich bases derived from isatin derivatives and N-[4-(4′-chlorophenyl) thiazol-2-yl] thiosemicarbazide. Eur. J. Pharm. Sci. 1999, 9, 25-31.
8. French, F. A.; Blanz, E. J. Jr. The carcinostatic activity of alpha-(N)-heterocyclic carboxaldehyde thiosemicarbazones. II. 3-Hydroxypyridine-2-carboxaldehyde thiosemicarbazone. Cancer Res. 1966, 26, 1638-1640.
9. DeConti, R. C.; Toftness, B. R.; Agrawal, K. C.; Tomchick, R.; Mead, J. A.; Bertino, J. R.; Sartorelli, A. C.; Creasey, W. A. Clinical and pharmacological studies with 5-hydroxy-2-formylpyridine thiosemicarbazone. Cancer Res. 1972, 32, 1455-1462.
10. Kalinowski, D. S.; Richardson, D. R. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol. Rev. 2005, 57, 547-583.
11. Krakoff, I. H.; Etcubanas, E.; Tan, C.; Mayer, K.; Bethune, V.; Burchenal, J. H. Clinical trial of 5-hydroxypicolinaldehyde thiosemicarbazone (5-HP; NSC-107392), with special reference to its ironchelating properties. Cancer Chemother. Rep. 1974, 58, 207-212.
12. Yuan, J.; Lovejoy, D. B.; Richardson, D. R. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 2004, 104, 1450-1458.
13. Richardson, D. R.; Sharpe, P. C.; Lovejoy, D. B.; Senaratne, D.; Kalinowski, D. S.; Islam, M.; Bernhardt, P. V. Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J. Med. Chem. 2006, 49, 6510-6521.
14. Kalinowski, D. S.; Yu, Y.; Sharpe, P. C.; Islam, M.; Liao, Y. T.; Lovejoy, D. B.; Kumar, N.; Bernhardt, P. V.; Richardson, D. R. Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents. J. Med. Chem. 2007, 50, 3716-3729.
15. Richardson, D. R.; Kalinowski, D. S.; Richardson, V.; Sharpe, P. C.; Lovejoy, D. B.; Islam, M.; Bernhardt, P. V. 2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity. J. Med. Chem. 2009, 52, 1459-1470.
16. Cai, L.; Li, X. K.; Song, Y.; Cherian, M. G. Essentiality, toxicology and chelation therapy of zinc and copper. Curr. Med. Chem. 2005, 12, 2753-2763.
17. Durham, T. R.; Snow, E. T. Metal ions and carcinogenesis. Experientia, Suppl. 2006, 97-130.
18. Green, D. A.; Antholine, W. E.; Wong, S. J.; Richardson, D. R.; Chitambar, C. R. Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase. Clin. Cancer Res. 2001, 7, 3574-3579.
19. De Domenico, I.; McVey Ward, D.; Kaplan, J. Regulation of iron acquisition and storage: consequences for iron-linked disorders. Nat. Rev. Mol. Cell Biol. 2008, 9, 72-81.
20. Toyokuni, S. Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci. 2009, 100, 9-16.
21. Kowdley, K. V. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 2004, 127, S79-S86.
22. Hentze, M. W.; Kuhn, L. C. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 8175-8182.
23. Richardson, D. R.; Ponka, P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim. Biophys. Acta 1997, 1331, 1-40.
24. Aisen, P. Transferrin receptor 1. Int. J. Biochem. Cell Biol. 2004, 36, 2137-2143.
25. Brinkmann, M.; Teuffel, R.; Laham, N.; Ehrlich, R.; Decker, P.; Lemonnier, F. A.; Pascolo, S. Expression of iron transport proteins divalent metal transporter-1, ferroportin-1, HFE and transferrin receptor-1 in human monocyte-derived dendritic cells. Cell Biochem. Funct. 2007, 25, 287-296.
26. Klausner, R. D.; Ashwell, G.; van Renswoude, J.; Harford, J. B.; Bridges, K. R. Binding of apotransferrin to K562 cells: explanation of the transferrin cycle. Proc. Natl. Acad. Sci. U.S.A. 1983, 80, 2263-2266.
27. Breuer, W.; Shvartsman, M.; Cabantchik, Z. I. Intracellular labile iron. Int. J. Biochem. Cell Biol. 2008, 40, 350-354.
28. Glickstein, H.; El, R. B.; Shvartsman, M.; Cabantchik, Z. I. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood 2005, 106, 3242-3250.
29. Zoller, H.; Theurl, I.; Koch, R.; Kaser, A.; Weiss, G. Mechanisms of iron mediated regulation of the duodenal iron transporters divalent metal transporter 1 and ferroportin 1. Blood Cells, Mol. Dis. 2002, 29, 488-497.
30. Rouault, T. A. Post-transcriptional regulation of human iron metabolism by iron regulatory proteins. Blood Cells, Mol. Dis. 2002, 29, 309-314.
31. Kato, J.; Kobune, M.; Ohkubo, S.; Fujikawa, K.; Tanaka, M.; Takimoto, R.; Takada, K.; Takahari, D.; Kawano, Y.; Kohgo, Y.; Niitsu, Y. Iron/IRP-1-dependent regulation of mRNA expression for transferrin receptor, DMT1 and ferritin during human erythroid differentiation. Exp. Hematol. 2007, 35, 879-887.
32. Richardson, D. R.; Neumannova, V.; Nagy, E.; Ponka, P. The effect of redox-related species of nitrogen monoxide on transferrin and iron uptake and cellular proliferation of erythroleukemia (K562) cells. Blood 1995, 86, 3211-3219.
33. Fillebeen, C.; Pantopoulos, K. Redox control of iron regulatory proteins. Redox Rep. 2002, 7, 15-22. (Pubitemid 34285103)
34. Nicolas, G.; Bennoun, M.; Devaux, I.; Beaumont, C.; Grandchamp, B.; Kahn, A.; Vaulont, S. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 8780-8785.
35. Rivera, S.; Liu, L.; Nemeth, E.; Gabayan, V.; Sorensen, O. E.; Ganz, T. Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood 2005, 105, 1797-1802. (Pubitemid 40223704)
36. Rivera, S.; Nemeth, E.; Gabayan, V.; Lopez, M. A.; Farshidi, D.; Ganz, T. Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood 2005, 106, 2196-2199. (Pubitemid 41291740)
37. Dunn, L. L.; Rahmanto, Y. S.; Richardson, D. R. Iron uptake and metabolism in the new millennium. Trends Cell Biol. 2007, 17, 93-100.
38. Nemeth, E.; Tuttle, M. S.; Powelson, J.; Vaughn, M. B.; Donovan, A.; Ward, D. M.; Ganz, T.; Kaplan, J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306, 2090-2093. (Pubitemid 40007660)
39. Fleming, M. D. The regulation of hepcidin and its effects on systemic and cellular iron metabolism. Hematol. Am. Soc. Hematol. Educ. Program 2008, 2008, 151-158
40. Chua, A. C.; Graham, R. M.; Trinder, D.; Olynyk, J. K. The regulation of cellular iron metabolism. Crit. Rev. Clin. Lab. Sci. 2007, 44, 413-459
41. Eisenstein, R. S. Iron regulatory proteins and the molecular control of mammalian iron metabolism. Annu. Rev. Nutr. 2000, 20, 627-662.
42. Kolberg, M.; Strand, K. R.; Graff, P.; Andersson, K. K. Structure, function, and mechanism of ribonucleotide reductases. Biochim. Biophys. Acta 2004, 1699, 1-34.
43. Elford, H. L.; Freese, M.; Passamani, E.; Morris, H. P. Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas. J. Biol. Chem. 1970, 245, 5228-5233.
44. Larrick, J. W.; Cresswell, P. Modulation of cell surface iron transferrin receptors by cellular density and state of activation. J. Supramol. Struct. 1979, 11, 579-586.
45. Sutherland, R.; Delia, D.; Schneider, C.; Newman, R.; Kemshead, J.; Greaves, M. Ubiquitous cell-surface glycoprotein on tumor cells is proliferation-associated receptor for transferrin. Proc. Natl. Acad. Sci. U.S.A. 1981, 78, 4515-4519.
46. Richardson, D. R.; Baker, E. The uptake of iron and transferrin by the human malignant melanoma cell. Biochim. Biophys. Acta 1990, 1053, 1-12.
47. Daniels, T. R.; Delgado, T.; Rodriguez, J. A.; Helguera, G.; Penichet, M. L. The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin. Immunol. 2006, 121, 144-158.
48. Daniels, T. R.; Delgado, T.; Helguera, G.; Penichet, M. L. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin. Immunol. 2006, 121, 159-176.
49. Yu, Y.; Kovacevic, Z.; Richardson, D. R. Tuning cell cycle regulation with an iron key. Cell Cycle 2007, 6, 1982-1994. (Pubitemid 47327885)
50. Bohnsack, B. L.; Hirschi, K. K. Nutrient regulation of cell cycle progression. Annu. Rev. Nutr. 2004, 24, 433-453.
51. Seligman, P. A.; Schleicher, R. B.; Siriwardana, G.; Domenico, J.; Gelfand, E. W. Effects of agents that inhibit cellular iron incorporation on bladder cancer cell proliferation. Blood 1993, 82, 1608-1617.
52. Lederman, H. M.; Cohen, A.; Lee, J. W.; Freedman, M. H.; Gelfand, E. W. Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. Blood 1984, 64, 748-753.
53. Noulsri, E.; Richardson, D. R.; Lerdwana, S.; Fucharoen, S.; Yamagishi, T.; Kalinowski, D. S.; Pattanapanyasat, K. Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells. Am. J. Hematol. 2009, 84, 170-176.
54. Gao, J.; Richardson, D. R. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. IV: The mechanisms involved in inhibiting cell-cycle progression. Blood 2001, 98, 842-850.
55. Richardson, D. R.; Tran, E. H.; Ponka, P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 1995, 86, 4295-4306.
56. Richardson, D. R.; Bernhardt, P. V. Crystal and molecular structure of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone (NIH) and its iron(III) complex: an iron chelator with anti-tumour activity. J. Biol. Inorg. Chem. 1999, 4, 266-273.
57. Kulp, K. S.; Green, S. L.; Vulliet, P. R. Iron deprivation inhibits cyclin-dependent kinase activity and decreases cyclin D/CDK4 protein levels in asynchronous MDA-MB-453 human breast cancer cells. Exp. Cell Res. 1996, 229, 60-68.
58. Simonart, T.; Degraef, C.; Andrei, G.; Mosselmans, R.; Hermans, P.; Van Vooren, J. P.; Noel, J. C.; Boelaert, J. R.; Snoeck, R.; Heenen, M. Iron chelators inhibit the growth and induce the apoptosis of Kaposi's sarcoma cells and of their putative endothelial precursors. J. Invest. Dermatol. 2000, 115, 893-900.
59. Sherr, C. J. G1 phase progression: cycling on cue. Cell 1994, 79, 551-555.
60. Liang, S. X.; Richardson, D. R. The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1. Carcinogenesis 2003, 24, 1601-1614.
61. Le, N. T.; Richardson, D. R. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood 2004, 104, 2967-2975.
62. Kovacevic, Z.; Richardson, D. R. The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis 2006, 27, 2355-2366.
63. Bandyopadhyay, S.; Pai, S. K.; Gross, S. C.; Hirota, S.; Hosobe, S.; Miura, K.; Saito, K.; Commes, T.; Hayashi, S.; Watabe, M.; Watabe, K. The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res. 2003, 63, 1731-1736. (Pubitemid 36460828)
64. Bandyopadhyay, S.; Pai, S. K.; Hirota, S.; Hosobe, S.; Takano, Y.; Saito, K.; Piquemal, D.; Commes, T.; Watabe, M.; Gross, S. C.; Wang, Y.; Ran, S.; Watabe, K. Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression. Oncogene 2004, 23, 5675-5681. (Pubitemid 39093045)
65. Maruyama, Y.; Ono, M.; Kawahara, A.; Yokoyama, T.; Basaki, Y.; Kage, M.; Aoyagi, S.; Kinoshita, H.; Kuwano, M. Tumor growth suppression in pancreatic cancer by a putative metastasis suppressor gene Cap43/NDRG1/Drg-1 through modulation of angiogenesis. Cancer Res. 2006, 66, 6233-6242.
66. Stein, S.; Thomas, E. K.; Herzog, B.; Westfall, M. D.; Rocheleau, J. V.; Jackson, R. S.2nd; Wang, M.; Liang, P. NDRG1 is necessary for p53-dependent apoptosis. J. Biol. Chem. 2004, 279, 48930-48940.
67. Ivan, M.; Kondo, K.; Yang, H.; Kim, W.; Valiando, J.; Ohh, M.; Salic, A.; Asara, J. M.; Lane, W. S.; Kaelin, W. G., Jr. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001, 292, 464-468.
68. Bruick, R. K. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 9082-9087.
69. Guo, K.; Searfoss, G.; Krolikowski, D.; Pagnoni, M.; Franks, C.; Clark, K.; Yu, K. T.; Jaye, M.; Ivashchenko, Y. Hypoxia induces the expression of the pro-apoptotic gene BNIP3. Cell Death Differ. 2001, 8, 367-376. (Pubitemid 32409607)
70. Mizutani, A.; Furukawa, T.; Adachi, Y.; Ikehara, S.; Taketani, S. A zinc-finger protein, PLAGL2, induces the expression of a proapoptotic protein Nip3, leading to cellular apoptosis. J. Biol. Chem. 2002, 277, 15851-15858.
71. Furukawa, T.; Adachi, Y.; Fujisawa, J.; Kambe, T.; Yamaguchi-Iwai, Y.; Sasaki, R.; Kuwahara, J.; Ikehara, S.; Tokunaga, R.; Taketani, S. Involvement of PLAGL2 in activation of iron deficient- and hypoxia-induced gene expression in mouse cell lines. Oncogene 2001, 20, 4718-4727. (Pubitemid 32762443)
72. Kalinowski, D. S.; Richardson, D. R. Future of toxicology - iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy. Chem. Res. Toxicol. 2007, 20, 715-720.
73. Bernhardt, P. V.; Sharpe, P. C.; Islam, M.; Lovejoy, D. B.; Kalinowski, D. S.; Richardson, D. R. Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity. J. Med. Chem. 2009, 52, 407-415.
74. Bernhardt, P. V. Coordination chemistry and biology of chelators for the treatment of iron overload disorders. Dalton Trans. 2007, 3214-3220.
75. Buss, J. L.; Torti, F. M.; Torti, S. V. The role of iron chelation in cancer therapy. Curr. Med. Chem. 2003, 10, 1021-1034.
76. Buss, J. L.; Greene, B. T.; Turner, J.; Torti, F. M.; Torti, S. V. Iron chelators in cancer chemotherapy. Curr. Top. Med. Chem. 2004, 4, 1623-1635.
77. Gojo, I.; Tidwell, M. L.; Greer, J.; Takebe, N.; Seiter, K.; Pochron, M. F.; Johnson, B.; Sznol, M.; Karp, J. E. Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies. Leuk. Res. 2007, 31, 1165-1173.
78. Knox, J. J.; Hotte, S. J.; Kollmannsberger, C.; Winquist, E.; Fisher, B.; Eisenhauer, E. A. Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161). Invest. New Drugs 2007, 25, 471-477. (Pubitemid 47222906)
79. Mackenzie, M. J.; Saltman, D.; Hirte, H.; Low, J.; Johnson, C.; Pond, G.; Moore, M. J. A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital phase II consortium. Invest. New Drugs 2007, 25, 553-1538
80. Brittenham, G. M. Iron chelators and iron toxicity. Alcohol 2003, 30, 151-158.
81. Hershko, C.; Abrahamov, A.; Konijn, A. M.; Breuer, W.; Cabantchik, I. Z.; Pootrakul, P.; Link, G. Objectives and methods of iron chelation therapy. Bioinorg. Chem. Appl. 2003, 151-168.
82. Olivieri, N. F.; Brittenham, G. M. Iron-chelating therapy and the treatment of thalassemia. Blood 1997, 89, 739-761.
83. Becton, D. L.; Bryles, P. Deferoxamine inhibition of human neuroblastoma viability and proliferation. Cancer Res. 1988, 48, 7189-7192. (Pubitemid 19014003)
84. Blatt, J. Deferoxamine in children with recurrent neuroblastoma. Anticancer Res. 1994, 14, 2109-2112.
85. Blatt, J.; Stitely, S. Antineuroblastoma activity of desferoxamine in human cell lines. Cancer Res. 1987, 47, 1749-1750. (Pubitemid 17056669)
86. Donfrancesco, A.; De Bernardi, B.; Carli, M.; Mancini, A.; Nigro, M.; De Sio, L.; Casale, F.; Bagnulo, S.; Helson, L.; Deb, G. Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: preliminary results. Italian Neuroblastoma Cooperative Group. Eur. J. Cancer 1995, 31A, 612-615.
87. Donfrancesco, A.; Deb, G.; Dominici, C.; Pileggi, D.; Castello, M. A.; Helson, L. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res. 1990, 50, 4929-4930. (Pubitemid 20257912)
88. Estrov, Z.; Tawa, A.; Wang, X. H.; Dube, I. D.; Sulh, H.; Cohen, A.; Gelfand, E. W.; Freedman, M. H. In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood 1987, 69, 757-761.
89. Selig, R. A.; White, L.; Gramacho, C.; Sterling-Levis, K.; Fraser, I. W.; Naidoo, D. Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts. Cancer Res. 1998, 58, 473-478. (Pubitemid 28087409)
90. Blatt, J.; Taylor, S. R.; Stitely, S. Mechanism of antineuroblastoma activity of deferoxamine in vitro. J. Lab. Clin. Med. 1988, 112, 433-436.
91. Wong, C.; Richardson, D. R. Beta-thalassaemia: emergence of new and improved iron chelators for treatment. Int. J. Biochem. Cell Biol. 2003, 35, 1144-1149.
92. Richardson, D. R. The controversial role of deferiprone in the treatment of thalassemia. J. Lab. Clin. Med. 2001, 137, 324-329.
93. Olivieri, N. F.; Brittenham, G. M.; McLaren, C. E.; Templeton, D. M.; Cameron, R. G.; McClelland, R. A.; Burt, A. D.; Fleming, K. A. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N. Engl. J. Med. 1998, 339, 417-423.
94. Maggio, A.; D'Amico, G.; Morabito, A.; Capra, M.; Ciaccio, C.; Cianciulli, P.; Di Gregorio, F.; Garozzo, G.; Malizia, R.; Magnano, C.; Mangiagli, A.; Quarta, G.; Rizzo, M.; D'Ascola, D. G.; Rizzo, A.; Midiri, M. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells, Mol. Dis. 2002, 28, 196-208. (Pubitemid 34743754)
95. Wanless, I. R.; Sweeney, G.; Dhillon, A. P.; Guido, M.; Piga, A.; Galanello, R.; Gamberini, M. R.; Schwartz, E.; Cohen, A. R. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 2002, 100, 1566-1569.
96. Anderson, L. J.; Wonke, B.; Prescott, E.; Holden, S.; Walker, J. M.; Pennell, D. J. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002, 360, 516-520.
97. Motekaitis, R. J.; Martell, A. E. Stabilities of the iron(III) chelates of 1,2-dimethyl-3-hydroxy-4-pyridinone and related ligands. Inorg. Chim. Acta 1991, 183, 71-80.
98. Cragg, L.; Hebbel, R. P.; Miller, W.; Solovey, A.; Selby, S.; Enright, H. The iron chelator L1 potentiates oxidative DNA damage in iron-loaded liver cells. Blood 1998, 92, 632-638. (Pubitemid 28323728)
99. Balfour, J. A. B.; Foster, R. H. Deferiprone: a review of its clinical potenitial in iron overload in B-thalassemia major and other transfusion-dependant disease. Drugs 1999, 58, 553-578.
100. Kontoghiorghes, G. J.; Neocleous, K.; Kolnagou, A. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Saf. 2003, 26, 553-584. (Pubitemid 36724096)
101. Singh, S.; Epemolu, R. O.; Dobbin, P. S.; Tilbrook, G. S.; Ellis, B. L.; Damani, L. A.; Hider, R. C. Urinary metabolic profiles in human and rat of 1,2-dimethyl- and 1,2-diethyl-substituted 3-hydroxypyridin-4-ones. Drug Metab. Dispos. 1992, 20, 256-261.
102. Liu, Z. D.; Hider, R. C. Design of clinically useful iron(III)-selective chelators. Med. Res. Rev. 2002, 22, 26-64.
103. Hider, R. C.; Liu, Z. D.; Piyamongkol, S. The design and properties of 3-hydroxypyridin-4-one iron chelators with high pFe(3+) values. Transfus. Sci. 2000, 23, 201-209.
104. Liu, Z. D.; Piyamongkol, S.; Liu, D. Y.; Khodr, H. H.; Lu, S. L.; Hider, R. C. Synthesis of 2-amido-3-hydroxypyridin-4(1H)-ones: novel iron chelators with enhanced pFe3+ values. Bioorg. Med. Chem. 2001, 9, 563-573.
105. Birch, N.; Wang, X.; Chong, H.-S. Iron chelators as therapeutic iron depletion agents. Expert Opin. Ther. Pat. 2006, 16, 1533-1556.
106. Bergeron, R. J.; McManis, J. S.; Franklin, A. M.; Yao, H.; Weimar, W. R. Polyamine-iron chelator conjugate. J. Med. Chem. 2003, 46, 5478-5483.
107. Ponka, P.; Borova, J.; Neuwirt, J.; Fuchs, O. Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett. 1979, 97, 317-321.
108. Ponka, P.; Borova, J.; Neuwirt, J.; Fuchs, O.; Necas, E. A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim. Biophys. Acta 1979, 586, 278-297.
109. Vitolo, L. M. W.; Hefter, G. T.; Clare, B. W.; Webb, J. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Part II. Formation constants with iron(III) and iron(II). Inorg. Chim. Acta 1990, 170, 171-176.
110. Avramovici-Grisaru, S.; Sarel, S.; Cohen, S.; Bauminger, R. E. The synthesis, crystal and molecular structure and oxidation state of iron complex from pyridoxal isonicotinoyl hydrazone and ferrous sulfate. Israel J. Chem. 1985, 25, 288-292.
111. Hermes-Lima, M.; Nagy, E.; Ponka, P.; Schulman, H. M. The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) protects plasmid pUC-18 DNA against *OH-mediated strand breaks. Free Radical Biol. Med. 1998, 25, 875-880.
112. Richardson, D. R.; Hefter, G. T.; May, P. M.; Webb, J.; Baker, E. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. III. Formation constants with calcium(II), magnesium(II) and zinc-(II). Biol. Met. 1989, 2, 161-167.
113. Whitnall, M.; Rahmanto, Y. S.; Sutak, R.; Xu, X.; Becker, E. M.; Mikhael, M. R.; Ponka, P.; Richardson, D. R. The MCK mouse heart model of Friedreich's ataxia: alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 9757-9762.
114. Baker, E.; Vitolo, M. L.; Webb, J. Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture. Biochem. Pharmacol. 1985, 34, 3011-3017.
115. Richardson, D. R.; Ponka, P. The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis. J. Lab. Clin. Med. 1994, 124, 660-671.
116. Ponka, P.; Schulman, H. M.; Wilczynska, A. Ferric pyridoxal isonicotinoyl hydrazone can provide iron for heme synthesis in reticulocytes. Biochim. Biophys. Acta 1982, 718, 151-156.
117. Brock, J. H.; Stevenson, J. Replacement of transferrin in serum-free cultures of mitogen-stimulated mouse lymphocytes by a lipophilic iron chelator. Immunol. Lett. 1987, 15, 23-25.
118. Blaha, K.; Cikrt, M.; Nerudova, J.; Ponka, H. F. Biliary iron excretion in rats following treatment with analogs of pyridoxal isonicotinoyl hydrazone. Blood 1998, 91, 4368-4372.
119. Link, G.; Ponka, P.; Konijn, A. M.; Breuer, W.; Cabantchik, Z. I.; Hershko, C. Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells. Blood 2003, 101, 4172-4179. (Pubitemid 36857901)
120. Brittenham, G. M. Pyridoxal isonicotinoyl hydrazone: an effective iron-chelator after oral administration. Semin. Hematol. 1990, 27, 112-116.
121. Hoy, T.; Humphrys, J.; Jacobs, A.; Williams, A.; Ponka, P. Effective iron chelation following oral administration of an isoniazid-pyridoxal hydrazone. Br. J. Hamaetol. 1979, 43, 443-449.
122. Cikrt, M.; Ponka, P.; Necas, E.; Neuwirt, J. Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone. Br. J. Hamaetol. 1980, 45, 275-283.
123. Richardson, D. R.; Vitolo, L. M. W.; Hefter, G. T.; Mat, P. M.; Clare, B. W.; Webb, J.; Wilairat, P. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Part I. Ionisation characteristics of the ligands and their relevance to biological properties. Inorg. Chim. Acta 1990, 170, 165-170.
124. Richardson, D. R.; Baker, E. The release of iron and transferrin from the human melanoma cell. Biochim. Biophys. Acta 1991, 1091, 294-302.
125. Buss, J. L.; Hermes-Lima, M.; Ponka, P. Pyridoxal isonicotinoyl hydrazone and its analogues. Adv. Exp. Med. Biol. 2002, 509, 205-229.
126. Johnson, D. K.; Pippard, M. J.; Murphy, T. B.; Rose, N. J. An in vivo evaluation of iron-chelating drugs derived from pyridoxal and its analogs. J. Pharmacol. Exp. Ther. 1982, 221, 399-403.
127. Richardson, D. R.; Milnes, K. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood 1997, 89, 3025-3038. (Pubitemid 27172591)
128. Richardson, D. R.; Ponka, P. Identification of a mechanism of iron uptake by cells which is stimulated by hydroxyl radicals generated via the iron-catalysed Haber-Weiss reaction. Biochim. Biophys. Acta 1995, 1269, 105-114.
129. Huang, A. R.; Ponka, P. A study of the mechanism of action of pyridoxal isonicotinoyl hydrazone at the cellular level using reticulocytes loaded with non-heme 59Fe. Biochim. Biophys. Acta 1983, 757, 306-315.
130. Richardson, D. R. Mobilization of iron from neoplastic cells by some iron chelators is an energy-dependent process. Biochim. Biophys. Acta 1997, 1320, 45-57.
131. Xu, X.; Sutak, R.; Richardson, D. R. Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking. Mol. Pharmacol. 2008, 73, 833-844.
132. Kwok, J. C.; Richardson, D. R. The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracyclinemediated cardiotoxicity. Redox Rep. 2000, 5, 317-324.
133. Chaston, T. B.; Lovejoy, D. B.; Watts, R. N.; Richardson, D. R. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin. Cancer Res. 2003, 9, 402-414.
134. Darnell, G.; Richardson, D. R. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation. Blood 1999, 94, 781-792.
135. Fu, D.; Richardson, D. R. Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. Blood 2007, 110, 752-761.
136. Nyholm, S.; Mann, G. J.; Johansson, A. G.; Bergeron, R. J.; Graslund, A.; Thelander, L. Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. J. Biol. Chem. 1993, 268, 26200-26205.
137. Thelander, L.; Graslund, A. Mechanism of inhibition of mammalian ribonucleotide reductase by the iron chelate of 1-formylisoquinoline thiosemicarbazone. Destruction of the tyrosine free radical of the enzyme in an oxygen-requiring reaction. J. Biol. Chem. 1983, 258, 4063-4066.
138. Thelander, L.; Graslund, A.; Thelander, M. Continual presence of oxygen and iron required for mammalian ribonucleotide reduction: possible regulation mechanism. Biochem. Biophys. Res. Commun. 1983, 110, 859-865.
139. Becker, E.; Richardson, D. R. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs. J. Lab. Clin. Med. 1999, 134, 510-521.
140. Cory, J. G.; Cory, A. H.; Rappa, G.; Lorico, A.; Liu, M. C.; Lin, T. S.; Sartorelli, A. C. Inhibitors of ribonucleotide reductase. Comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones. Biochem. Pharmacol. 1994, 48, 335-344.
141. Cory, J. G.; Cory, A. H.; Rappa, G.; Lorico, A.; Liu, M. C.; Lin, T. S.; Sartorelli, A. C. Structure-function relationships for a new series of pyridine-2-carboxaldehyde thiosemicarbazones on ribonucleotide reductase activity and tumor cell growth in culture and in vivo. Adv. Enzyme Regul. 1995, 35, 55-68.
142. Wong, C. S.; Kwok, J. C.; Richardson, D. R. PCTH: a novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice. Biochim. Biophys. Acta 2004, 1739, 70-80.
143. Bernhardt, P. V.; Chin, P.; Richardson, D. R. Unprecedented oxidation of a biologically active aroylhydrazone chelator catalysed by iron(III): serendipitous identification of diacylhydrazine ligands with high iron chelation efficacy. J. Biol. Inorg. Chem. 2001, 6, 801-809.
144. Bernhardt, P. V.; Caldwell, L. M.; Chaston, T. B.; Chin, P.; Richardson, D. R. Cytotoxic iron chelators: characterization of the structure, solution chemistry and redox activity of ligands and iron complexes of the di-2-pyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues. J. Biol. Inorg. Chem. 2003, 8, 866-880.
145. Becker, E. M.; Lovejoy, D. B.; Greer, J. M.; Watts, R.; Richardson, D. R. Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and antitumour agents. Br. J. Pharmacol. 2003, 138, 819-830.
146. Chaston, T. B.; Watts, R. N.; Yuan, J.; Richardson, D. R. Potent antitumor activity of novel iron chelators derived from di-2-pyridylketone isonicotinoyl hydrazone involves fenton-derived free radical generation. Clin. Cancer Res. 2004, 10, 7365-7374.
147. Kalinowski, D. S.; Sharpe, P. C.; Bernhardt, P. V.; Richardson, D. R. Design, synthesis, and characterization of new iron chelators with anti-proliferative activity: structure-activity relationships of novel thiohydrazone analogues. J. Med. Chem. 2007, 50, 6212-6225.
148. Sartorelli, A. C.; Agrawal, K. C.; Tsiftsoglou, A. S.; Moore, E. C. Characterization of the biochemical mechanism of action of alpha-(N)- heterocyclic carboxaldehyde thiosemicarbazones. Adv. Enzyme Regul. 1976, 15, 117-139.
149. Spingarn, N. E.; Sartorelli, A. C. Synthesis and evaluation of the thiosemicarbazone, dithiocarbazonate, and 2′-pyrazinylhydrazone of pyrazinecarboxaldehyde as agents for the treatment of iron overload. J. Med. Chem. 1979, 22, 1314-1316.
150. Mohan, M.; Kumar, M.; Kumar, A.; Madhuranath, P. H.; Jha, N. K. Synthesis, spectroscopic, and antitumor activity of metal chelates of S-methyl-N-(l-isoquinolyl)-methylendithiocarbazate. J. Inorg. Biochem. 1988, 33, 121-129.
151. West, D. X.; Liberta, A. E.; Padhye, S. B.; Chikate, R. C.; Sonawane, P. B.; Kumbhar, A. S.; Yerande, R. G. Thiosemicarbazone complexes of copper(II): structural and biological studies. Coord. Chem. Rev. 1993, 123, 49-71.
152. Kowol, C. R.; Eichinger, R.; Jakupec, M. A.; Galanski, M.; Arion, V. B.; Keppler, B. K. Effect of metal ion complexation and chalcogen donor identity on the antiproliferative activity of 2-acetylpyridine N,N-dimethyl(chalcogen) semicarbazones. J. Inorg. Biochem. 2007, 101, 1946-1957.
153. Bermejo, E.; Carballo, R.; Castineiras, A.; Dominguez, R.; Liberta, A. E.; Maichle-Mossmer, C.; Salberg, M. M.; West, D. X. Synthesis, structural characteristics, and biological activities of complexes of ZnII, CdII, HgII, PdII, and PtII with 2-acetylpyridine-4-methylthiosemicarbazone. Eur. J. Inorg. Chem. 1999, 965-973.
154. Li, J.; Luo, X.; Wang, Q.; Zheng, L.-M.; King, I.; Doyle, T. W.; Chen, S.-H. Synthesis and biological evaluation of a water soluble phosphate prodrug of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP). Bioorg. Med. Chem. Lett. 1998, 8, q3159-3164.
155. Li, J.; Zheng, L. M.; King, I.; Doyle, T. W.; Chen, S. H. Syntheses and antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarbazone (3-AMP), 3-amino-pyridine-2-carboxaldehydethiosemicarbazone (3-AP) and its water-soluble prodrugs. Curr. Med. Chem. 2001, 8, 121-133.
156. Bernhardt, P. V.; Chin, P.; Sharpe, P. C.; Richardson, D. R. Hydrazone chelators for the treatment of iron overload disorders: iron coordination chemistry and biological activity. Dalton Trans. 2007, 3232-3244. (Pubitemid 47484833)
157. Bernhardt, P. V.; Wilson, G. J.; Sharpe, P. C.; Kalinowski, D. S.; Richardson, D. R. Tuning the antiproliferative activity of biologically active iron chelators: characterization of the coordination chemistry and biological efficacy of 2-acetylpyridine and 2-benzoylpyridine hydrazone ligands. J. Biol. Inorg. Chem. 2008, 13, 107-119.
158. Rudnev, A. V.; Foteeva, L. S.; Kowol, C.; Berger, R.; Jakupec, M. l. A.; Arion, V. B.; Timerbaev, A. R.; Keppler, B. K. Preclinical characterization of anticancer gallium(III) complexes: solubility, stability, lipophilicity and binding to serum proteins. J. Inorg. Biochem. 2006, 100, 1819-1826.
159. Kowol, C. R.; Berger, R.; Eichinger, R.; Roller, A.; Jakupec, M. A.; Schmidt, P. P.; Arion, V. B.; Keppler, B. K. Gallium(III) and iron(III) complexes of alpha-N-heterocyclic thiosemicarbazones: synthesis, characterization, cytotoxicity, and interaction with ribonucleotide reductase. J. Med. Chem. 2007, 50, 1254-1265.
160. Grguric-Sipka, S.; Kowol, C. R.; Valiahdi, S.-M.; Eichinger, R.; Jakupec, M. A.; Roller, A.; Shova, S.; Arion, V. B.; Keppler, B. K. Ruthenium(II) complexes of thiosemicarbazones: the first water-soluble complex with pH-dependent antiproliferative activity. Eur. J. Inorg. Chem. 2007, 2870-2878.
161. Graminha, A. E.; Rodrigues, C.; Batista, A. A.; Teixeira, L. R.; Fagundes, E. S.; Beraldo, H. Ruthenium(II) complexes of 2-benzoylpyridine- derived thiosemicarbazones with cytotoxic activity against human tumor cell lines. Spectrochim. Acta, Part A 2008, 69A, 1073-1076.
162. Gomez-Saiz, P.; Garcia-Tojal, J.; Diez-Gomez, V.; Gil-Garcia, R.; Pizarro, J. L.; Arriortua, M. I.; Rojo, T. Indirect evidences of desulfurization of a thiosemicarbazonecopper(II) system in aqueous basic medium. Inorg. Chem. Commun. 2005, 8, 259-262.
163. Finch, R. A.; Liu, M. C.; Cory, A. H.; Cory, J. G.; Sartorelli, A. C. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity. Adv. Enzyme Regul. 1999, 39, 3-12.
164. Finch, R. A.; Liu, M.; Grill, S. P.; Rose, W. C.; Loomis, R.; Vasquez, K. M.; Cheng, Y.; Sartorelli, A. C. Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem. Pharmacol. 2000, 59, 983-991.
165. Murren, J.; Modiano, M.; Clairmont, C.; Lambert, P.; Savaraj, N.; Doyle, T.; Sznol, M. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Clin. Cancer Res. 2003, 9, 4092-4100.
166. Ma, B.; Goh, B. C.; Tan, E. H.; Lam, K. C.; Soo, R.; Leong, S. S.; Wang, L. Z.; Mo, F.; Chan, A. T.; Zee, B.; Mok, T. A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thio semicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells. Invest. New Drugs 2008, 26, 169-173. (Pubitemid 351357710)
167. Amendola, V.; Boiocchi, M.; Fabbrizzi, L.; Mosca, L. Metal-controlled anion-binding tendencies of the thiourea unit of thiosemicarbazones. Chem. - Eur. J. 2008, 14, 9683-9696.
168. Shao, J.; Zhou, B.; Di Bilio, A. J.; Zhu, L.; Wang, T.; Qi, C.; Shih, J.; Yen, Y. A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase. Mol. Cancer Ther. 2006, 5, 586-592.
169. Antholine, W.; Knight, J.; Whelan, H.; Petering, D. H. Studies of the reaction of 2-formylpyridine thiosemicarbazone and its iron and copper complexes with biological systems. Mol. Pharmacol. 1977, 13, 89-98.
170. Saryan, L. A.; Mailer, K.; Krishnamurti, C.; Antholine, W.; Petering, D. H. Interaction of 2-formylpyridine thiosemicarbazonato copper (II) with Ehrlich ascites tumor cells. Biochem. Pharmacol. 1981, 30, 1595-1604.
171. Attia, S.; Kolesar, J.; Mahoney, M. R.; Pitot, H. C.; Laheru, D.; Heun, J.; Huang, W.; Eickhoff, J.; Erlichman, C.; Holen, K. D. A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. Invest. New Drugs 2008, 26, 369-379.
172. Karp, J. E.; Giles, F. J.; Gojo, I.; Morris, L.; Greer, J.; Johnson, B.; Thein, M.; Sznol, M.; Low, J. A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders. Leuk. Res. 2008, 32, 71-77.
173. Odenike, O. M.; Larson, R. A.; Gajria, D.; Dolan, M. E.; Delaney, S. M.; Karrison, T. G.; Ratain, M. J.; Stock, W. Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest. New Drugs 2008, 26, 233-239.
174. Lovejoy, D. B.; Richardson, D. R. Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells. Blood 2002, 100, 666-676.
175. Whitnall, M.; Howard, J.; Ponka, P.; Richardson, D. R. Aclass of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 14901-14906.
176. Rao, V. A.; Klein, S. R.; Agama, K. K.; Toyoda, E.; Adachi, N.; Pommier, Y.; Shacter, E. B. The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells. Cancer Res. 2009, 69, 948-957.
177. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23, 3-25.
178. Agarwal, R. P.; Perrin, D. D. Computer-based approach to chelation therapy: a theoretical study of some chelating agents for the selective removal of toxic metal ions from plasma. Agents Actions 1976, 6, 667-673.
179. Shipman, C., Jr.; Smith, S. H.; Drach, J. C.; Klayman, D. L. Antiviral activity of 2-acetylpyridine thiosemicarbazones against herpes simplex virus. Antimicrob. Agents Chemother. 1981, 19, 682-685.
180. Klayman, D. L.; Scovill, J. P.; Bruce, J.; Bartosevich, J. F. 2-Acetylpyridine thiosemicarbazones. 8. Derivatives of 1-acetylisoquinoline as potential antimalarial agents. J. Med. Chem. 1984, 27, 84-87.
181. Brown, R. E.; Stancato, F. A.; Wolfe, A. D. Preferential inhibition of ribonucleic acid synthesis by a new thiosemicarbazone possessing antibacterial and antiparasitic properties. Antimicrob. Agents Chemother. 1981, 19, 234-237.
182. Klayman, D. L.; Bartosevich, J. F.; Griffin, T. S.; Mason, C. J.; Scovill, J. P. 2-Acetylpyridine thiosemicarbazones. 1. A new class of potential antimalarial agents. J. Med. Chem. 1979, 22, 855-862.
183. Klayman, D. L.; Scovill, J. P..; et al. 2-Acetylpyridine thiosemicarbazones. 3. Selenium analogs as potential anti-malarial agents. Eur. J. Med. Chem. 1981, 16, 317-320.
184. Kowol, C. R.; Reisner, E.; Chiorescu, I.; Arion, V. B.; Galanski, M.; Deubel, D. V.; Keppler, B. K. An electrochemical study of antineoplastic gallium, iron and ruthenium complexes with redox noninnocent alpha-N-heterocyclic chalcogensemicarbazones. Inorg. Chem. 2008, 47, 11032-11047.
185. Bernhardt, P. V.; Mattsson, J.; Richardson, D. R. Complexes of cytotoxic chelators from the dipyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues. Inorg. Chem. 2006, 45, 752-760.
186. Ghose, A. K.; Crippen, G. M. Atomic physicochemical parameters for three-dimensional-structure-directed quantitative structure-activity relationships. 2. Modeling dispersive and hydrophobic interactions. J. Chem. Inf. Comput. Sci. 1987, 27, 21-35.